FHL2 and cardiac hypertrophy: On the contrary, fhl2−/− mice presented with a comparable magnitude of cardiac hypertrophy relative to wild-type controls after TAC [34,35], but mounted an exaggerated hypertrophic response after chronic β-adrenergic receptor stimulation by isoproterenol infusion [33], suggesting an anti-hypertrophic role for FHL2 in the latter setting.